Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis

Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, invasive procedures are still required for diagnosis. Herein, we developed a novel ultrasensitive pipeline to detect circulating tumor DNA (ctDNA) in a series of 75 plasma samples from localized BC patients prior to any medical intervention. We first performed a tumor-informed analysis to correlate the mutations found in tumor tissue and plasma. Disregarding the tumor data next, we developed an approach to detect tumor mutations in plasma. We observed a mutation concordance between the tumor and plasma of 29.50% with a sensitivity down to 0.03% in mutant variant allele frequency (VAF). We detected mutations in 33.78% of the samples, identifying eight patients with plasma-only mutations. Altogether, we determined a specificity of 86.36% and a positive predictive value of 88.46% for BC detection. We demonstrated an association between higher ctDNA median VAF and higher tumor grade, multiple plasma mutations with a likelihood of relapse and more frequent TP53 plasma mutations in hormone receptor-negative tumors. Overall, we have developed a unique ultra-sensitive sequencing workflow with a technology not previously employed in early BC, paving the way for its application in BC screening.Comino-Mendez’s contract is funded by the Spanish Association Against Cancer Scientific Foundation (AECC). This study was supported by the “Consejería de Salud y Familias—Junta de Andalucía” (PI-0291-2019), “Fundación Unicaja” is funding Alba-Bernal’s contract and the Andalusia-Roche Network in Precision Medical Oncology Quirós-Ortega’s contract. Carbajosa-Antona’s contract is funded by the “Ayudas María Zambrano para la atracción de talento internacional—Universidad de Málaga”. Partial funding for open access charge: Universidad de Málag

Pros and cons of different therapeutic antibody formats for recombinant antivenom development.

Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively

A coat-independent superinfection exclusion rapidly imposed in Nicotiana benthamiana cells by tobacco mosaic virus is not prevented by depletion of the movement protein

[EN] New evidence is emerging which indicates that population variants in plant virus infections are not uniformly distributed along the plant, but structured in a mosaic-like pattern due to limitation to the superinfection imposed by resident viral clones. The mechanisms that prevent the infection of a challenge virus into a previously infected cell, a phenomenon known as superinfection exclusion (SE) or Homologous Interference, are only partially understood. By taking advantage of a deconstructed tobacco mosaic virus (TMV) system, where the capsid protein (CP) gene is replaced by fluorescent proteins, an exclusion mechanism independent of CP was unveiled. Time-course superinfection experiments provided insights into SE dynamics. Initial infection levels affecting less than 10 % of cells led to full immunization in only 48 h, and measurable immunization levels were detected as early as 6 h post-primary infection. Depletion of a functional movement protein (MP) was also seen to slow down, but not to prevent, the SE mechanism. These observations suggest a CP-independent mechanism based on competition for a host-limiting factor, which operates at very low virus concentration. The possible involvement of host factors in SE has interesting implications as it would enable the host to influence the process.We wish to acknowledge Dr. Victor Klimyuk and Dr. Yuri Gleba from ICON-Genetics for kindly providing the MagnICON vectors. Thanks also to Dr. George Lomonossof for providing the pEAQ vectors. This work was supported by Projects BIO2010-15384 and IPT-2011-0720-010000 from the Spanish Ministry of Economy and Competitiveness.Julve Parreño, JM.; Gandia Fernàndez, A.; Fernandez Del Carmen, MA.; Sarrion-Perdigones, A.; Castelijns, B.; Granell Richart, A.; Orzáez Calatayud, DV. (2013). A coat-independent superinfection exclusion rapidly imposed in Nicotiana benthamiana cells by tobacco mosaic virus is not prevented by depletion of the movement protein. Plant Molecular Biology. 81(6):553-564. doi:10.1007/s11103-013-0028-1S553564816Abel PP, Nelson RS, De B, Hoffmann N, Rogers SG, Fraley RT, Beachy RN (1986) Delay of disease development in transgenic plants that express the tobacco mosaic virus coat protein gene. Science 232(4751):738–743Abramoff MD, Magalhaes PJ, Ram SJ (2004) Image processing with imageJ. Biophotonics Int 11(7):36–42Benbasat JA, Burck KB, Miller RC Jr (1978) Superinfection exclusion and lack of conservative transfer of bacteriophage T7 DNA. Virology 87(1):164–171Bendahmane M, Beachy RN (1999) Control of tobamovirus infections via pathogen-derived resistance. Adv Virus Res 53:369–386Bendahmane M, Fitchen JH, Zhang G, Beachy RN (1997) Studies of coat protein-mediated resistance to tobacco mosaic tobamovirus: correlation between assembly of mutant coat proteins and resistance. J Virol 71(10):7942–7950Bendahmane M, Chen I, Asurmendi S, Bazzini AA, Szecsi J, Beachy RN (2007) Coat protein-mediated resistance to TMV infection of Nicotiana tabacum involves multiple modes of interference by coat protein. Virology 366(1):107–116Dietrich C, Maiss E (2003) Fluorescent labelling reveals spatial separation of potyvirus populations in mixed infected Nicotiana benthamiana plants. J Gen Virol 84(10):2871–2876Elena SF, Bedhomme S, Carrasco P, Cuevas JM, de la Iglesia F, Lafforgue G, Lalic J, Prosper A, Tromas N, Zwart MP (2011) The evolutionary genetics of emerging plant RNA viruses. Mol Plant Microbe Interact 24(3):287–293Ellenberg P, Linero FN, Scolaro LA (2007) Superinfection exclusion in BHK-21 cells persistently infected with Junín virus. J Gen Virol 88(10):2730–2739Folimonova SY (2012) Superinfection exclusion is an active virus-controlled function that requires a specific viral protein. J Virol 86(10):5554–5561Folimonova SY, Robertson CJ, Shilts T, Folimonov AS, Hilf ME, Garnsey SM, Dawson WO (2010) Infection with strains of Citrus tristeza virus does not exclude superinfection by other strains of the virus. J Virol 84(3):1314–1325Fulton RW (1986) Practices and precautions in the use of cross protection for plant-virus disease-control. Annu Rev Phytopathol 24:67–81Genovés A, Pallás V, Navarro JA (2011) Contribution of topology determinants of a viral movement protein to its membrane association, intracellular traffic, and viral cell-to-cell movement. J Virol 85(15):7797–7809Giritch A, Marillonnet S, Engler C, van Eldik G, Botterman J, Klimyuk V, Gleba Y (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci U S A 103(40):14701–14706Gleba Y, Marillonnet S, Klimyuk V (2004) Engineering viral expression vectors for plants: the ‘full virus’ and the ‘deconstructed virus’ strategies. Curr Opin Plant Biol 7(2):182–188Gleba Y, Klimyuk V, Marillonnet S (2005) Magnifection—a new platform for expressing recombinant vaccines in plants. Vaccine 23(17–18):2042–2048Gleba Y, Marillonnet S, Klimyuk V (2006) High throughput gene assembly and expression using viral RNA replicons delivered by agrobacterium. In Vitro Cell Dev Biol Anim 42:10A–10AGonzalez-Jara P, Fraile A, Canto T, Garcia-Arenal F (2009) The multiplicity of infection of a plant virus varies during colonization of its eukaryotic host. J Virol 83(15):7487–7494Gopinath K, Wellink J, Porta C, Taylor KM, Lomonossoff GP, van Kammen A (2000) Engineering cowpea mosaic virus RNA-2 into a vector to express heterologous proteins in plants. Virology 267(2):159–173Kawakami S, Watanabe Y, Beachy RN (2004) Tobacco mosaic virus infection spreads cell to cell as intact replication complexes. Proc Natl Acad Sci U S A 101(16):6291–6296Kliem M, Dreiseikelmann B (1989) The superimmunity gene sim of bacteriophage P1 causes superinfection exclusion. Virology 171(2):350–355Koo JC, Asurmendi S, Bick J, Woodford-Thomas T, Beachy RN (2004) Ecdysone agonist-inducible expression of a coat protein gene from tobacco mosaic virus confers viral resistance in transgenic Arabidopsis. Plant J 37(3):439–448Lee Y-M, Tscherne DM, Yun S-I, Frolov I, Rice CM (2005) Dual mechanisms of pestiviral superinfection exclusion at entry and RNA replication. J Virol 79(6):3231–3242Lu B, Stubbs G, Culver JN (1998) Coat protein interactions involved in tobacco mosaic tobamovirus cross-protection. Virology 248(2):188–198Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, Gleba Y (2004) In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci USA 101(18):6852–6857Marillonnet S, Thoeringer C, Kandzia R, Klimyuk V, Gleba Y (2005) Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat Biotechnol 23(6):718–723Michel N, Allespach I, Venzke S, Fackler OT, Keppler OT (2005) The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr Biol 15(8):714–723Nakazono-Nagaoka E, Takahashi T, Shimizu T, Kosaka Y, Natsuaki T, Omura T, Sasaya T (2009) Cross-protection against bean yellow mosaic virus (BYMV) and clover yellow vein virus by attenuated BYMV isolate M11. Phytopathology 99(3):251–257Nejidat A, Beachy RN (1989) Decreased levels of TMV coat protein in transgenic tobacco plants at elevated temperatures reduce resistance to TMV infection. Virology 173(2):531–538Orzaez D, Mirabel S, Wieland WH, Granell A (2006) Agroinjection of tomato fruits. A tool for rapid functional analysis of transgenes directly in fruit. Plant Physiology 140(1):3–11Powell PA, Sanders PR, Tumer N, Fraley RT, Beachy RN (1990) Protection against tobacco mosaic virus infection in transgenic plants requires accumulation of coat protein rather than coat protein RNA sequences. Virology 175(1):124–130Ramirez S, Perez-del-Pulgar S, Carrion JA, Coto-Llerena M, Mensa L, Dragun J, Garcia-Valdecasas JC, Navasa M, Forns X (2010) Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. J Gen Virol 91(Pt 5):1183–1188Ranade K, Poteete AR (1993) Superinfection exclusion (sieB) genes of bacteriophages P22 and lambda. J Bacteriol 175(15):4712–4718Roossinck MJ (2005) Symbiosis versus competition in plant virus evolution. Nat Rev Microbiol 3(12):917–924Sainsbury F, Thuenemann EC, Lomonossoff GP (2009) pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol J 7(7):682–693Sarkar S, Smitamana P (1981) A proteinless mutant of tobacco mosaic virus: evidence against the role of a viral coat protein for interference. Mol Gen Genet 184(1):158–159Syller J (2012) Facilitative and antagonistic interactions between plant viruses in mixed infections. Mol Plant Pathol 13(2):204–216Takahashi T, Sugawara T, Yamatsuta T, Isogai M, Natsuaki T, Yoshikawa N (2007) Analysis of the spatial distribution of identical and two distinct virus populations differently labeled with cyan and yellow fluorescent proteins in coinfected plants. Phytopathology 97(10):1200–1206Tscherne DM, Evans MJ, von Hahn T, Jones CT, Stamataki Z, McKeating JA, Lindenbach BD, Rice CM (2007) Superinfection exclusion in cells infected with hepatitis C virus. J Virol 81(8):3693–3703Voinnet O, Rivas S, Mestre P, Baulcombe D (2003) An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus. Plant J 33(5):949–956Walkey DGA, Lecoq H, Collier R, Dobson S (1992) Studies on the control of zucchini yellow mosaic-virus in courgettes by mild strain protection. Plant Pathol 41(6):762–771Zaitlin M, Palukaitis P (2000) Advances in understanding plant viruses and virus diseases. Annu Rev Phytopathol 38:117–143Ziebell H, Carr JP (2010) Chapter 6—Cross-protection: a century of mystery. In: John PC, Gad L (eds) Advances in virus research, vol 76. Academic Press, London, pp 211–264Zou G, Zhang B, Lim P-Y, Yuan Z, Bernard KA, Shi P-Y (2009) Exclusion of West Nile virus superinfection through RNA replication. J Virol 83(22):11765–1177

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis.

Circulating tumor DNA (ctDNA) has emerged as a non-invasive "liquid biopsy" for early breast cancer diagnosis. We evaluated the suitability of ctDNA analysis in the diagnosis of early breast cancer after mammography findings, comparing PIK3CA and TP53 mutations between tumor biopsies and pre-biopsy circulating DNA. Matched plasma and frozen fresh tissue biopsies from patients with Breast Imaging-Reporting and Data System (BIRADS) 4c/5 mammography findings and subsequent diagnosis of primary breast cancer were analyzed using NGS TruSeq Custom Amplicon Low Input Panel (Illumina) and plasma SafeSEQ (Sysmex Inostics). The same plasma and tumor mutations were observed in eight of 29 patients (27.6%) with four in TP53 and five in PIK3CA mutations. Sequencing analysis also revealed four additional ctDNA mutations (three in TP53 and one in PIK3CA) previously not identified in three patients tissue biopsy. One of these patients had mutations in both genes. Age, tumor grade and size, immunohistochemical (IHC) subtype, BIRADS category, and lymph node positivity were significantly associated with the detectability of these blood tumor-derived mutations. In conclusion, ctDNA analysis could be used in early breast cancer diagnosis, providing critical clinical information to improve patient diagnosis

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis

Circulating tumor DNA (ctDNA) has emerged as a non-invasive “liquid biopsy” for early breast cancer diagnosis. We evaluated the suitability of ctDNA analysis in the diagnosis of early breast cancer after mammography findings, comparing PIK3CA and TP53 mutations between tumor biopsies and pre-biopsy circulating DNA. Matched plasma and frozen fresh tissue biopsies from patients with Breast Imaging-Reporting and Data System (BIRADS) 4c/5 mammography findings and subsequent diagnosis of primary breast cancer were analyzed using NGS TruSeq Custom Amplicon Low Input Panel (Illumina) and plasma SafeSEQ (Sysmex Inostics). The same plasma and tumor mutations were observed in eight of 29 patients (27.6%) with four in TP53 and five in PIK3CA mutations. Sequencing analysis also revealed four additional ctDNA mutations (three in TP53 and one in PIK3CA) previously not identified in three patients tissue biopsy. One of these patients had mutations in both genes. Age, tumor grade and size, immunohistochemical (IHC) subtype, BIRADS category, and lymph node positivity were significantly associated with the detectability of these blood tumor-derived mutations. In conclusion, ctDNA analysis could be used in early breast cancer diagnosis, providing critical clinical information to improve patient diagnosis

Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis

Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, invasive procedures are still required for diagnosis. Herein, we developed a novel ultrasensitive pipeline to detect circulating tumor DNA (ctDNA) in a series of 75 plasma samples from localized BC patients prior to any medical intervention. We first performed a tumor-informed analysis to correlate the mutations found in tumor tissue and plasma. Disregarding the tumor data next, we developed an approach to detect tumor mutations in plasma. We observed a mutation concordance between the tumor and plasma of 29.50% with a sensitivity down to 0.03% in mutant variant allele frequency (VAF). We detected mutations in 33.78% of the samples, identifying eight patients with plasma-only mutations. Altogether, we determined a specificity of 86.36% and a positive predictive value of 88.46% for BC detection. We demonstrated an association between higher ctDNA median VAF and higher tumor grade, multiple plasma mutations with a likelihood of relapse and more frequent TP53 plasma mutations in hormone receptor-negative tumors. Overall, we have developed a unique ultra-sensitive sequencing workflow with a technology not previously employed in early BC, paving the way for its application in BC screening